 |
- Last updated refers to the date when our listing for each treatment was last updated.
- ID is our internal ID - starting with VT.
- Min Karnofsky is a general guide to how well you have to function to use this treatment
- For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.
|
|
|
|
|
|
Treatment Name: |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
|
|
|
|
|
Keywords: |
|
Vorinostat, Temozolomide |
|
|
|
|
Phase: |
|
Phase 1 |
|
|
|
|
|
|
Treatment ID#s: |
|
VT1679
NCT00268385
|
|
|
|
|
Age Group: |
|
Adults Only |
|
|
|
|
|
|
Min Karnofsky Score: |
|
60: Requires occasional assistance but is able to care for most of own needs |
|
|
|
|
Conditions: |
|
Newly Diagnosed: Y
Recurrent: Y
Prior Surgery is Allowed
Prior Radiation is Allowed
Prior Chemotherapy is Allowed
Patients with histologically proven intracranial malignant glioma including glioblastoma multiforme, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, or malignant astrocytoma (not otherwise specified) |
|
|
|
|
|
|
Last Updated: |
|
04/15/2008 |
|
|
|
|
Tumor Types: |
|
Anaplastic Astrocytoma
Glioblastoma Multiforme
Gliosarcoma
Mixed Glioma
Oligodendroglioma High Grade |
|
|
|
|
|
|
|
Comments: |
|
Suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase inhibitor that has demonstrated potent antitumor effects in vitro and in vivo and shows significant synergistic activity against glioblastoma when combined with either temozolomide or BCNU. Early results from phase I trials suggest that SAHA is well tolerated, and dose-limiting toxicities do not overlap with those of temozolomide. |
|
|
|
|
|
|
Treatment Type: |
|
Chemotherapy
Immunological, Biological or Targeted Therapy. |
|
|
|
|
Contact: |
|
UCLA Medical Center
Timothy Cloughesy, MD
Director, Neuro-Oncology Program
710 Westwood Plaza
Reed Bldg, Room 1-230
Los Angeles, CA 90095
Phone:310-825-5321
Fax: (310)825-0644
Click here to send an email
Website: www.neurooncology.ucla.edu
Dana-Farber Cancer Institute
Patrick Wen, MD
Center for Neuro-Oncology
Boston, MA
Phone:617-632-6327
Email not available
The Brain Tumor Center at Duke
David Reardon, MD
Rm 047 Baker House, Hospital South
Trent Drive
Durham, NC 27710
Phone:(919)684-5301
Fax: (919)684-6674
Click here to send an email
Website: www.cancer.duke.edu/btc
Memorial Sloan-Kettering Cancer Center
Lauren Abrey, MD
Dept. Of Neurology
1275 York Ave
New York, NY 10021
Phone:(212)639-5122
Fax: (212)717-3551
Click here to send an email
MD Anderson Cancer Center
Jan Esenwein
Program Coordinator, Brain Tumor Program
Contact: Jan Esenwein or Marie Woodward
1515 Holcombe Blvd
Houston, TX 77030-
Phone:(713)745-2264
Fax: (713)794-4999
Click here to send an email
Website: www.mdanderson.org/diseases/braincancer/ |
|
|
|
|
